{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 7 of 51', 'Study ID RCB: 2020-A00652-37', '2', 'List of Abbreviations', 'ADR:', 'Adverse Drug Reaction', 'AE:', 'Adverse Event', 'CRF:', 'Case Report Form', 'CRO:', 'Contract Research Organization', 'DLQI:', 'Dermatology Quality of Life Index', 'HCP:', 'Healthcare Practitioner', 'IEC:', 'Independent Ethics Committee', 'IRB:', 'Institutional Review Board', 'LEO', 'LEO Pharma A/S and/or affiliates or representatives', 'MedDRA:', 'Medical dictionary for Regulatory Activities', 'NIS:', 'Non-Interventional Study', 'OE:', 'Other Experience', 'PASI:', 'Psoriasis Area and Severity Index', 'PRO:', 'Patient Reported Outcome', 'QoL:', 'Quality of Life', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 8 of 51', 'Study ID RCB: 2020-A00652-37', '3', 'Responsible Parties', 'Sponsor : LEO pharma France', '2 Rue Ren\u00e9 Caudron', '78960 Voisins-le-Bretonneux', 'France', 'Study Sponsor Contact: Yassmina Mandouri', '2 Rue Ren\u00e9 Caudron,', '78960 Voisins-le-Bretonneux', 'Email yamfr @leo-pharma.com', 'Contract Research Organization: CLINACT', 'V\u00e9lizy Espace, b\u00e2timent Santos Dumont', '13 Avenue Morane Saulnier', '78140 V\u00e9lizy-Villacoublay', 'Coordinating Investigator:', 'Dr Ziad REGUIAI', 'Polyclinique Reims-Bezannes', '89 Rue Victor De Broglie', '51430 Bezannes, FRANCE', 'Scientific committee:', 'Dr Pierre-Dominique GHISLAIN', 'Cliniques Universitaires Saint Luc - Universit\u00e9 Catholique de Louvain', 'Avenue Hippocrate 10,', '1200 Woluwe- Saint-Lambert', 'Dr Thierry BOYE', \"H\u00f4pital d'Instruction des arm\u00e9es SAINTE ANNE (TOULON)\", 'BCRM TOULON 2 boulevard Sainte Anne BP 600 - 83800 TOULON Cedex 9', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 9 of 51', 'Study ID RCB: 2020-A00652-37', 'Dr Ziad REGUIAI', 'Polyclinique Reims-Bezannes', '89 Rue Victor De Broglie', '51430 Bezannes, France', 'LEO Pharma legal entity is the sponsor of the study and the Contract Research Organisation(s)', '(CRO) CLINACT is authorised by LEO to act on behalf of LEO. LEO Pharma 2 Rue Ren\u00e9 Caudron,', '78960 Voisins-le-Bretonneux, France will be the Data Controller.', 'Contact and responsibilities of all parties contributing to the study, including all investigators,', 'are detailed in a stand-alone document available upon request to LEO. For key contributors,', 'e.g. national coordinating investigators, LEO will keep CVs and documentation regarding', 'Conflicts of Interest and make such documentation available upon request from relevant', 'parties, e.g. authorities, journals. LEO will keep a record of all relevant sponsor personnel.', 'CLINACT will keep a record of all involved CRO personnel.', 'The following essential documents must be in the hands of LEO before the study is initiated at', 'a site:', 'Written agreement between LEO or CLINACT and the Study Site Responsible / Clinic', '/', 'Hospital.', 'Signed and dated protocol agreement and amendment agreements, if any, with the', 'original signature of the Site Responsible.', 'Patient Information Sheet and Informed Consent Form in local language (notified to /', 'approved by Independent Ethics Committees (IECs).', 'Written IEC / IRB approval.', 'Competent Authority notification.', 'Product liability insurance.', 'LEO safety plan which is a three party agreement between Global safety, Safety contact', 'person and the CRO on the handling of safety reporting', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']\n\n###\n\n", "completion": "END"}